Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children

Expert Review of Anti-Infective Therapy

Volumn 4, Issue 1, 2006, Pages 91-100

  Marcinak, John F ^a   Frank, Arthur L ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Clidamycin; Community associated; Community onset; Methicillin resistance; Panton Valentine leukocidin; Staphylococcus aureus; Tetracyclines; Trimethoprim sulfamethoxazole

Indexed keywords

AZITHROMYCIN; BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GLYCOPEPTIDE; GLYCYLCYCLINE DERIVATIVE; KETOLIDE; LEUKOCIDIN; LINEZOLID; MACROLIDE; MINOCYCLINE; MONOCLONAL ANTIBODY; PENICILLIN BINDING PROTEIN; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINUPRISTIN; RECOMBINASE; RIFAMPICIN; SULFAMETHOXAZOLE; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL CHROMOSOME; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; CHILD; CLINICAL FEATURE; COMMUNICABLE DISEASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; GENE CASSETTE; GENE FUNCTION; GENETIC ANALYSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; IN VITRO STUDY; MEDICAL RESEARCH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; PATHOGENESIS; PATHOGENICITY; PEDIATRICS; PRACTICE GUIDELINE; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; UNITED STATES; VIRULENCE; CLASSIFICATION; DRUG EFFECT; GENETICS; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PENICILLIN RESISTANCE; PRESCHOOL CHILD; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33645063756     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.4.1.91     Document Type: Review

References (69)

1. Crawford SE, Daum RS. Epidemic community-associated methicillin resistant Staphyloccus aureus. Pediatr Infect Dis. J. 24, 459-460 (2005).
2. Ryback MJ, LaPlante KL. Community-associated methicillin-resistant Staphylocoocus aureus: a review. Pharmacotherapy 25(1), 74-85 (2005).
3. Siberry GK. Fighting a rising tide of MRSA infection in the young. Contemp. Pediatr. 22(7), 44-53 (2005).
4. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. 40, 562-573 (2005).
5. Zetola N, Francis JS, Nuermberger EL et al. Community-acquired methicillin-resistant Staphyloccus aureus: an emerging threat. Lancet Infect. Dis. 5, 275-286 (2005).
6. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureur: a meta-analysis of prevalence and risk factors. Clin. Infect. Dis. 36, 131-139 (2003).
7. Robinson DA, Kearns AM, Holmes A et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone. Lancet 365, 1256-1258 (2005).
8. Frank AL, Marcinak, JF, Mangat PD et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Fediatr. Infect. Dis. J. 21, 530-534 (2002).
9. Kaplan SL, Hulten KG, Gonzalez BE et al. Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin. Infect. Dis. 40, 1785-1791 (2005).
10. Purcell K, Fergie JE. Exponential increase in community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children. Pediatr. Infect. Dis. J. 21, 988-989 (2002).
11. Dietrich DW, Auld DB, Mermel LA. Community-acquired methicillin-resistant Staphylococcus aureus in southeastern New England. Pediatrics 113, e347-e352 (2004).
12. Campbell AL, Bryant KA, Stover B et al. Epidemiology of Staphylococcus aureus infection at a children's hospital. Infect. Control Hosp. Epidemiol. 24, 427-430 (2003).
13. Schulz R, Allen M, Murray Q. Infections due to community-acquired methicillin-resistant Staphylococcus aureus: an emergent epidemic in Kentucky. J. Ky. Med. Assoc. 103(5), 194-203 (2005).
14. Buckingham SC, McDougal LK, Cathey LD et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus: at a Memphis, Tennessee Childreds Hospital. Pediatr. inlect. Dis. J. 23, 619-624 (2004).
15. Vandenesch F, Naimi T, Enright MC et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg. Infect. Dis. 9, 978-983 (2003).
16. Wu KC, Chiu. HH, Wang JH et al. Characteristics of community-acquired methicillin-resistant Staphylococcus aureus in infants and children without known risk factors. J. Microbiol. Immunol. Infect. 35, 53-56 (2002).
17. Wang CC, Lo WT Chu ML, Siu LK. Epidemiological typing of community-acquired methicillin-resistant Staphylococcus aureus solates from children in Taiwan. Clin. Infect. Dis. 39, 481-487 (2004).
18. Weber JT. Community-associated methicillin-resistant Staphylococcus aureus. Clin,. Infect. Dis. 41, S269-S272 (2005).
19. McDougal LK, Steward CD, Kiligore GE et al. Pulsed-field electrophoresis typing of oxaciffin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41, 5113-5120 (2003).
20. Centers for Disease Control and Prevention. Four pediatric deaths from community- acquired methicillin-resistant Siaphylococcus aureus - Minnesota and North Dakota, 1997-1999. Morb. Mortal. Wkly. Rep. 48, 707-710 (1999).
21. Mishaan AMA, Mason EO Jr, Martinez-Aguilar G et al. Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas. Pediatr. Infect. Dis. J. 24, 201-206 (2005).
22. Kazakova SV, Hageman JC, Matava M et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N. Engl. J Med 352, 468-475 (2005).
23. Pan ES, Diep BA, Charlebois ED et al. Population dynamics of nasal strains of methicillin-resistant staphylococcus aureus- and their relation to community-associated disease activity. Clin. Infect. Dis. 192, 811-818 (2005).
24. Fridkin SK, Hageman JC, Morrison M et al Methicillin-resistant Staphylococcus aureus disease in three communities. N. Engl. J. Med. 352,1436-1444 (2005).
25. Alfaro C, Fergie J Purcell K. Emergence of community-acquired methicillin-resistant Staphylococcus aureus in complicated parapneumonic effusions. Pediatr. Infect. Dis. J 24, 274-275 (2005).
26. Gonzalez BE, Hulten KG, Dishop MK et al. Pulmonary manifestions in children with invasive community-acquired Staphylococcus aureus infection. Clin. Infect. Dis. 41, 583-590 (2005).
27. Martinez-Aguilar G, Avalos-Mishaan A, Hulten K et al. Community-acquired methicillin-resistant and methicillin- susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect. Dis. J 23, 701-706 (2004).
28. Mongkolrattanothai K, Boyle S, Kahana MD et al. Severe Staphy1ococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicitlin-resistant isolates. Clin. Infect. Dis. 37, 1050-1058 (2003).
29. Gonzalez BE, Martinez-Aguilar G, Hulten KG etal. Severe staphylococcus sepsis in adolescents in the era of community- acquired methicillin-resistant Staphylococcus aureus. Pediatrics 115, 642-648 (2005).
30. Adem PV, Montgomery CP, Husain AN et al. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. N Engl. J Med. 353, 1245-1251 (2005).
31. Chambers HE Community-associated MRSA - resistance and virulence converge. N. Engl. J Med. 352, 1485-1487 (2005).
32. Lee MC, Rio AM, Fonseca Aten M et al. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr. Infect. Dis. J 23, 123-1279 (2004).
33. Ma XX, Ito T, Tiensasitorn C et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired. methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. 46, 1147-1152 (2002).
34. Daum RS, Ito T, Hiramatsu K et al. A novel methicillin-resistance cassette in community-acquired methicillin-resistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis. 186, 1344-1347(2002).
35. Ito T, Ma XX, Takeuchi F et al. Novel Type V staphylococcal cassette chromosome mec driven by a novel chromosome recombinase, ccrC. Antimicrob. Agents Chermother. 46, 1147-1152 (2004).
36. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. 34, 482-492 (2002).
37. Lewis JS II, Jorgensen JH. Inducible clindamycin resistance in staphylococci: should clinicians and microbiologists be concerned? Clin. Infect. Dis. 40, 280-285 (2005).
38. Siberry GK, Tekle T, Carroll K et al. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. 37, 1257-1260 (2003).
39. Chavez-Bueno S, Bozogan B, Katz K et al. Inducible clindamycin resistance and molecular epiderniologic trends of pediatric community-acquired methicillin-resistant Staphycococcus aureus in Dallas, Texas. Antimicrob. Agents Chemother. 49(6). 2283-2288 (2005).
40. Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and healthcare-associated methicillin-resistant Staphylococcus aureus infection. JAMA 290, 2976-2984 (2003).
41. Bratu S, Eramo A, Kopec R et al. Community-associated methicillin- resistant Staphylococcus aureus in hospital nursery and maternity units. Emerg. Infect. Dis. 11, 808-813 (2005).
42. Baggett HC, Hennessy TW, Rudolph K et al. Community-onset methicillin- resistant Staphylococcus auerus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J. Infect. Dis. 189, 1565-1573 (2004).
43. Yamasaki O, Kaneko J, Morizane S et al. The association between Staphylococcus aureus carrying Panton-Valentine leukocidin genes and the development of deep-seated follicular infection. Clin. Infect. Dis. 40, 381-385 (2005).
44. Etienne J. Panton-Valentine leukocidin: a marker of severity for Staphylococcus aureus infection? Clin. Infect. Dis. 41, 591-593 (2005).
45. Gillet Y, Issartel B, Vanhems P et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359(9308), 753-759 (2002).
46. Kaplan SL. Treatment of community- associated methicillin-resistant Staphylcococcus aureus infections. Pediatr. Infect. Dis. J 24 (5), 457-458 (2005).
47. Marcinak JF, Frank AL. Treatment of community-acquired methicillin-resistant Staphylococcus aureus in children. Curr. Opin. Infect Dus. 16, 265-269 (2003).
48. Chicago Department of Public Health. MRSA in Chicago: guidelines for the primary care provider. Monthly Morbid. Rep. 7(3), 1-4 (2005).
49. Baker CJ, Frenck RW. Change in the management of skin/soft tissue infections needed. AAP News 45(3), 105-107 (2004).
50. Iyer S, Jones DH. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am. Acad Dermatol. 50, 854-858 (2003).
51. Martinez-Aguilar G, Hammerman WA, Mason EO, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr. Infect. Dis. J. 22, 593-598 (2003).
52. Johnigan RH, Pereira KD, Poole MD. Community-acquired methicillin-resistant Staphylcoccus aureus in children and adolescents - changing trends. Arch. Otolaryngol. Head Neck. Surg. 129, 1049-1052 (2003).
53. Schreckenberger PC, Ilendo E, Ristow KL. Incidence of constitutive and inducible clindamycin resistance in Stapbylococcus aureus and coagulase-negative staphylococci in a community and a tertiary care hospital. Clin. Microblol. 42(6), 2777-2779 (2004).
54. Zelazny AM, Ferraro MJ, Glermen A. Selection of strains for quality assessment of the disk induction method for detection of inducible clindamycin resistance in staphylococci: a CLSI Collaborative Study. J. Clin. Microbiol. 43(6), 2613-2615 (2005).
55. Steward CD, Raney PM, Morrell AK et al. Testing for induction of clindamycin resistance in erythromycin-resistant isolates of Staphylococcus aureus. J. Clin. Microbiol. 43(4), 1716-1721 (2005).
56. Kaplan SL, Afghani B, Pio L et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infectons in children. Pediatr. Inlect. Dis. J 22(9 Suppl.), S176-S185 (2003).
57. Healy CM, Hulten KG, Palazzi DL, Campbell JR, Baker CJ. Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin. Infect. Dis. 39, 1460-1466 (2004).
58. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin. Infect. Dis. 38, 864-870 (2004).
59. Coyle EA, Cha R, Ryback MJ. Influences of linezolid, penicillin and clindamcyin, alone and in combination, on streptococcal pyrogenic exotoxin A release. Antibicrob. Agents Chemother. 47(5), 1752-1755 (2003).
60. Bernardo K, Pakulat N, Fleer S et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob. Agents Chemother. 48(2), 546-555 (2004).
61. Wargo KA, Eilland EH. Appropriate antimicrobial therapy for comunity- acquired methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes (letter) Clin. Infect. Dis. 40, 1376-1377 (2005).
62. Shelburne SA, Musher DM, Hulten K et al. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob. Agents Chemother 48(10), 4016-4019 (2004).
63. Strydewski ME, O'Riordan WD, Lau WK et al. Telavancin versus standard therapy for treatment of complicated skin and soft tissue infections due to Gram-positive bacteria. Clin. Infect. Dis. 40, 1601-1607 (2005).
64. Goergens ED, McEvoy A, Watson M, Barrett IR. Acute osteomyelitis and septic arthritis in children. J. Pediatr Child Health. 41, 59-62 (2005).
65. Gerencer RZ. Successful out-patient treatment of sinusitis exacerbations caused by cornmunity-acquired methicillin-resistant Staphylococcus aureus. Otololaryngol. Head Neck Surg. 132(6), 828-833 (2005).
66. Rube JJ, Monson T, Bradsher RW, Menon A. Use of long acting tetracyclines for methicillin resistant Staphylococcus aureus infections: case series and review of the literature. Clin. Infect. Dis. 40, 1429-1434 (2005).
67. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin. Infect. Dis. 41 (Suppl. 5), S303-S314 (2005).
68. Carpenter CF, Chambers HF. Daptomycin: another novel Agent for treating infections due to drug-resistant Gram-positive pathogens. Clin. Infect. Dis. 38, 994-1000 (2004).
69. Lonks JR, Goldmann DA. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Clin. Infect. Dis. 40, 1657-1664 (2005).